Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient ...

Senseonics Holdings Inc (SENS) reports impressive revenue growth and strategic advancements, despite facing challenges in ...

Q3 2025 Earnings Call Transcript November 5, 2025 Senseonics Holdings, Inc. misses on earnings expectations. Reported EPS is ...

Senseonics (SENS) stock falls as the company posts strong Q3 growth but set its 2025 revenue outlook below consensus. Read ...

Fintel reports that on November 6, 2025, HC Wainwright & Co. maintained coverage of Senseonics Holdings (NYSEAM:SENS) with a ...

Germantown-based Senseonics Holdings Inc. (SENS) on Wednesday reported a loss of $19.5 million in its third quarter.

Direct to Consumer (DTC) leads have doubled in Q4 compared to the pre-launch third quarter New patient shipments of approximately 600 in December were the highest monthly total in the Company’s ...

GERMANTOWN, Md., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...

“We received FDA approval for Eversense 365 in the third quarter, and Mercy completed the first commercial patient insertion of our new sensor last month. This marks a significant achievement for ...

Generated revenue of $6.6 million in the second quarter of 2025, an increase of 37% versus the second quarter of 2024, driven by 79% new patient growth in the U.S. over prior year Expanded ...

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes ...

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...